Lazard Asset Management LLC Makes New $707,000 Investment in PROCEPT BioRobotics Corporation $PRCT

Lazard Asset Management LLC acquired a new stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 28,261 shares of the company’s stock, valued at approximately $707,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC lifted its holdings in PROCEPT BioRobotics by 7.3% during the 1st quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock valued at $1,101,000 after purchasing an additional 1,286 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in PROCEPT BioRobotics by 9.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock worth $8,923,000 after buying an additional 13,767 shares during the last quarter. Intech Investment Management LLC grew its stake in PROCEPT BioRobotics by 54.4% during the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock worth $1,654,000 after buying an additional 10,002 shares during the last quarter. Prudential Financial Inc. increased its holdings in shares of PROCEPT BioRobotics by 100.4% during the second quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock worth $393,000 after buying an additional 3,415 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of PROCEPT BioRobotics by 6.9% during the second quarter. State Street Corp now owns 1,269,110 shares of the company’s stock worth $73,101,000 after buying an additional 81,849 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

Analysts Set New Price Targets

PRCT has been the topic of several recent analyst reports. Leerink Partners downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $31.00 to $29.00 in a report on Thursday, June 11th. Wells Fargo & Company cut PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a report on Wednesday. TD Cowen cut their price objective on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday. Wall Street Zen raised PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.00.

PROCEPT BioRobotics Trading Up 5.8%

Shares of NASDAQ PRCT opened at $19.34 on Thursday. PROCEPT BioRobotics Corporation has a 1-year low of $16.67 and a 1-year high of $47.97. The company has a 50-day moving average of $21.85 and a two-hundred day moving average of $24.89. The company has a market cap of $1.10 billion, a PE ratio of -9.97 and a beta of 0.89. The company has a current ratio of 6.73, a quick ratio of 5.51 and a debt-to-equity ratio of 0.15.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The company had revenue of $94.50 million for the quarter, compared to the consensus estimate of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.10%. PROCEPT BioRobotics’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period last year, the company earned ($0.35) earnings per share. As a group, equities analysts expect that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current fiscal year.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Second-quarter revenue rose 19.3% year over year to $94.5 million, exceeding analysts’ $92.77 million estimate. The result suggests continued demand for PROCEPT’s urology-focused robotic systems despite broader concerns about customer inventory. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management forecast fiscal 2026 revenue of $390 million to $410 million, a range that broadly brackets the $397.2 million consensus estimate and may have eased concerns about a sharp near-term slowdown.
• Neutral Sentiment: The company reported an adjusted loss of $0.47 per share, narrowly missing the $0.46 consensus estimate and worsening from a $0.35 loss in the year-ago quarter. PROCEPT remains unprofitable, with analysts expecting a full-year loss. PROCEPT BioRobotics Reports Q2 Loss, Beats Revenue Estimates
• Negative Sentiment: Wells Fargo downgraded PROCEPT from “overweight” to “equal weight” and set a $19 price target, signaling limited upside at recent trading levels. Wells Fargo downgrade report
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who purchased PRCT shares from February 28, 2024, through February 25, 2026. The allegations include material misstatements about product demand, excess customer inventory, and late-quarter bulk discounts that may have overstated recurring-revenue trends. Investors seeking lead-plaintiff status generally face a September 22, 2026 deadline. Levi & Korsinsky PROCEPT class action alert

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.